Rasio rega marang prakiraan pendapatan: Impact BioMedical, Inc. (IBO)
Impact BioMedical Inc conducts research on botanical extracts in the US, which determines the dynamics of the future P/S metric. Capitalization is based on patent royalties, although the dispersion of resources creates margin risks. The current status is 1016.10, while this chart demonstrates the current balance of supply and demand, helping to assess the degree of undervaluation or the weakness of this asset.
Rincian analitis perusahaan impactbiomedinc.com (IBO)
- rega pasar lan target rega analis:
- indikator kapitalisasi bursa perusahaan:
- indikator nilai buku ekuitas:
- indikator beban utang lan likuiditas:
Rasio Total Utang marang Ekuitas Impact BioMedical Inc|IBO - Rasio silihan jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Impact BioMedical|IBO - Kewajiban utang agregat|Utang-utang marang kapitalisasi buku Impact BioMedical Inc|IBO - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Impact BioMedical|Likuiditas cepet impactbiomedinc.com
- rincian asil keuangan lan kelipatan valuasi:
IBO - Penghasilan resik perusahaan|Bathi sing dikarepake Impact BioMedical Inc|IBO - Koefisien rega marang bathi|Pangali Forward P/E Impact BioMedical Inc|IBO - Rega marang bathi kanthi panyesuaian wutah|Pangali EV/EBITDA Impact BioMedical Inc|IBO - Bathi operasional sadurunge amortisasi|Bathi resik saben saham (EPS TTM) Impact BioMedical|IBO - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi EPS kuartalan impactbiomedinc.com|IBO - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep Impact BioMedical Inc
- data total pendapatan lan volume dodolan:
Ringkesan analisis perusahaan:Impact BioMedical Inc IBO
The forward P/S ratio determines the market value of the business relative to expected annual sales, allowing for an assessment of capitalization sensitivity to potential cash gaps. By analyzing the history of the forward P/S valuation, an investor can correlate the growth rates of Impact BioMedical Inc (IBO) with the success of Linebacker antiseptic licensing and the rigor of FDA inspections affecting the company's future revenue.
Karo sapa Impact BioMedical Inc saingan
Rasio rega marang prakiraan pendapatan Haleon HLN|KVUE - Multiplikator forward rega marang pendapatan|VRNA - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan MENS|LGND: Multiplikator Forward P/S|amneal.com (AMRX) - Multiplikator Forward P/S|PRGO (Perrigo) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Alvotech S.A. (ALVO)|Multiplikator forward rega marang pendapatan LQDA (Liquidia Technologies)|Rasio rega marang pendapatan sing dikarepake GLPG|ANI Pharmaceuticals - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan MNKD|Amphastar Pharmaceuticals, Inc. - Multiplikator Forward P/S|PCRX: Rasio rega marang prakiraan pendapatan|SPRY: Multiplikator Forward P/S|TBPH - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Aquestive Therapeutics|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep scPharma SCPH|Rasio rega marang prakiraan pendapatan Tectonic Therapeutic, Inc. (TECX)|Multiplikator forward rega marang pendapatan Tonix Pharma TNXP|Multiplikator Forward P/S SXTC (China SXT Pharmaceuticals, Inc.)|Eupraxia Pharmaceuticals, Inc. (EPRX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|BioHarvest Sciences - Multiplikator Forward P/S|EXOZ (invizyne.com) - Kapitalisasi marang prakiraan pendapatan|ORMP: Multiplikator Forward P/S|ENTX - Rasio kapitalisasi marang dodolan sing dikarepake|HYFT (MindWalk) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan ABVC BioPharma, Inc (ABVC)|Multiplikator Forward P/S CPIX|Multiplikator Forward P/S quantumbiopharma.com (QNTM)|Rasio rega marang prakiraan pendapatan FibroGen FGEN|Telomir Pharmaceuticals Inc - Rasio rega marang prakiraan pendapatan|RANI: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan SNYR (Synergy CHC Corp)|RLYB: Multiplikator Forward P/S|LEXX - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Pulmatrix|Kapitalisasi marang prakiraan pendapatan PTHL (Pheton)|Multiplikator Forward P/S APM|Multiplikator forward rega marang pendapatan Lyra Therapeutics Inc LYRA|Multiplikator Forward P/S TNFA (TNF Pharmaceuticals, Inc.)|Rasio kapitalisasi marang dodolan sing dikarepake cbdMD Inc. (YCBD)|PainReform - Multiplikator Forward P/S|CYTO: Rasio rega marang prakiraan pendapatan|Lipella (LIPO) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep OptiNose Corp (OPTN)|Rasio rega marang prakiraan pendapatan Pieris Pharmaceuticals|procapsgroup.com - Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S PTPI|QLI (Qilian International Holding Group) - Rega forward marang dodolan|Multiplikator Forward P/S SLRN (ACELYRIN, Inc.)|Multiplikator Forward P/S TFF Pharmaceuticals, Inc TFFP
